Ropivacaine Cabi 10 mg/ml 20 ml, 5 pcs.

A long-acting local anesthetic of the amide type, which is a pure enantiomer. It has both anesthetic and analgesic effect. By reversibly blocking potential-dependent Na+-channels it prevents generation of impulses in the endings of sensitive nerves and conduction of impulses along the nerve fibers.

Indications

At concentrations of 7.5 mg/1 ml and 10 mg/1 ml, Ropivacaine Cabi is used v adults and children over 12 years of age for the following indications:

Anesthesia in surgical procedures:

Intraarticular injection in knee arthroscopy.

At a concentration of 2 mg/1 ml, Ropivacaine Kabi is used for the following indications:

Cutting acute pain syndrome in adults and children over 12 years of age.

Active ingredient

How to take, the dosage

The drug is used for perineural administration (spinal and conduction anesthesia).

Ropivacaine Kabi should only be administered by or under the supervision of professionals with sufficient experience in local anesthesia and with resuscitation equipment and medications available.

Adults and children over 12 years of age

In general, higher doses and more concentrated solutions of the drug are required for anesthesia in surgical procedures than are used for anesthetic purposes. For analgesia (e.g., epidural administration to suppress acute pain), lower concentrations and doses are recommended and a dose of 2 mg/1 ml is usually recommended. For intraarticular administration, a dose of 7.5 mg/1 ml is recommended. Ropivacaine Kabi 10 mg/1 mL is recommended for epidural anesthesia when complete motor blockade is necessary for surgery.

The following tables are a guide to dosage selection for the more commonly used blockades. A minimum dosage sufficient to form an effective blockade should be used. The experience of the clinical specialist and knowledge of the patient’s physical condition are important in deciding the dosage.

Table 1. Dosage recommendations for Ropivacaine Cabi for adults and children over 12 years of age

The dosages listed in Table 1 are considered sufficient for a successful blockade and should serve as a guide for use in adult patients, as there are individual variations in the timing and duration of the block. The values in the “Dose” column represent the expected range of averaged doses needed.

Ropivacaine Kabi dosing recommendations for adults and children over 12 years of age:

* The dosage for conduction anesthesia should be specified according to the site of application and the patient’s condition. Lumbar and supraclavicular brachial plexus blocks may result in a higher incidence of adverse reactions regardless of the local anesthetic used.

** Cases of chondrolysis have been reported with postoperative prolonged intra-articular infusion of local anesthetics. Ropivacaine Kabi should not be used for prolonged intra-articular administration.

*** If Ropinvacaine Kabi has additionally been used for other types of anesthesia, the maximum dose should not exceed 225 mg.

1 – Stepwise dosing should be used, with a starting dose of approximately 100 mg (97.55 mg=13 ml, 105 mg=14 ml) and administered within 3-5 minutes. Two additional doses, totaling an additional 50 mg, can be administered as needed.

2 – N/A = not valid.

The standard guidelines should be used to familiarize yourself with the factors affecting the method of performing individual blockades and the requirements for specific patient groups.

In order to prevent the anesthetic from entering the vascular stream, aspiration testing should always be performed prior to and during the administration of the drug. If a large dose of the drug must be administered, a test dose of 3-5 ml of lidocaine with epinephrine is recommended. Accidental intravascular injection is recognized by a temporary increase in HR, and accidental intrathecal injection by signs of spinal block. If toxic symptoms occur, the drug administration should be stopped immediately.

Aspiration should be performed prior to and during administration of the main dose, which should be administered slowly or in increments of 25-50 mg/min, while carefully observing the patient’s vital functions and maintaining verbal contact with the patient.

The single infusion of Ropivacaine Cabi for surgical epidural block in doses up to 250 mg is generally well tolerated by patients.

In brachial plexus blockade with 40 ml of Ropivacaine Kabi 7.5 mg/1 ml, maximum plasma concentrations of ropivacaine in some patients may reach a value characterized by mild CNS toxicity symptoms. Therefore, the use of a dose higher than 40 ml of Ropivacaine Kabi 7.5 mg/1 ml (300 mg ropivacaine) is not recommended.

When using prolonged blockade either by continuous infusion or by repeated bolus administration, the risks of reaching toxic plasma concentrations or of local nerve damage must be taken into account. Ropnvacaine infusion for 24 hours at a dose of up to 800 mg total for surgical procedures and for postoperative pain relief, as well as extended epidural infusion after surgery at up to 28 mg/h for 72 hours is well tolerated by adult patients.

The following method is recommended for postoperative pain management: if an epidural catheter was not inserted during surgery, an epidural block with a bolus injection of Ropivacaine Cabi 7.5 mg/1 ml is performed after insertion. Analgesia is supported by an infusion of Ropivacaine Kabi 2 mg/1 ml. In most cases for moderate to severe postoperative pain, infusion at a rate of 6-14 ml/h (12-28 mg/h) provides adequate analgesia with minimal non-progressive motor blockade (a significant reduction in the need for opioid analgesics was observed with this technique). For postoperative analgesia, Ropivacaine Kabi 2 mg/1 ml can be administered continuously as an epidural infusion for 72 h without fentanyl or in combination with it (1-4 µg/ml). Ropivacaine Kabi 2 mg/1 mL (6-14 mL/hr) provided adequate analgesia in most patients.

The combination of Ropivacaine Kabi and fentanyl resulted in improved analgesia, while causing side effects common to narcotic analgesics.

The use of Ropivacaine Kabi concentrations greater than 7.5 mg/1 ml in cesarean sections has not been studied.

Renal impairment

In general, no change in dose is necessary when administering a single dose or short-term therapy in patients with impaired renal function.

Hepatic impairment

Ropivacaine is metabolized in the liver and, therefore, should be used with caution in patients with severe liver disease. Repeated doses may need to be reduced due to delayed excretion.

Patients with hypovolemia

Patients with hypovolemia may develop acute and severe hypotension during epidural anesthesia for any reason, regardless of the use of local anesthetic.

Table 2. Dosing recommendations for Ropivacaine Kabi for children 0 to 12 years old

a – Smaller doses from the suggested dosing interval are recommended for thoracic and epidural blocks, whereas larger doses are recommended for lumbar and caudal epidural blocks.

b – Recommended for lumbar epidural blocks. A lower bolus dose in the case of thoracic level analgesia is warranted.

The dosages in Table 2 should be considered guidelines for the use of the drug in pediatric practice. At the same time, there is individual variability in the rate at which the block develops and its duration. In overweight children, a gradual reduction of the drug dose is often required, and the patient’s ideal body weight should be considered as the basis. For factors affecting specific block techniques and individual patient requirements, the data given in the standard guidelines should be considered. The volume for a single caudal block and the volume for epidural bolus doses should not exceed 25 ml in any patient.

Before and during injection, careful aspiration is recommended to prevent intravascular injection. The patient’s vital functions should be closely monitored during the administration of the drug. In case of toxic symptoms, the infusion should be stopped immediately. A single caudal epidural injection of ropivacaine at a dose of 2 mg/1 ml (at the rate of 2 mg/kg, solution volume 1 ml/kg) forms adequate postoperative analgesia below T1/2 in most patients.

Children over 4 years of age tolerate doses of 3 mg/kg well. The amount of epidural solution administered at the caudal level can be varied to achieve different prevalence of sensory block, as described in specialized guidelines.

Whatever the type of anesthesia, bolus administration of the calculated dose is recommended.

The use of the drug in concentrations higher than 5 mg/1 ml as well as intrathecal administration of Ropivacaine Kabi in children has not been studied.

The use of ropivacaine has not been studied in preterm infants regardless of the route of administration.

Interaction

This medicinal product should not be mixed with other medicinal products.

The simultaneous use of Ropivacaine Cabi with local anesthetics, drugs structurally similar to local amide anesthetics or drugs depressing the central nervous system (CNS) may increase the toxic effects of the drugs.

In alkaline solutions, ropivacaine hydrochloride may precipitate because it is weakly soluble at pH >6.0).

Special Instructions

Anesthesia must be performed by experienced specialists, in specially equipped rooms. The availability of equipment and medications for resuscitation measures is mandatory. The patient must have an intravenous catheter inserted before the conductive blocks are started.

The clinician must be familiar with precautions and have adequate experience in diagnosing and treating possible side effects, systemic toxicity and other complications such as irreversible subarachnoid injection, which can cause severe spinal block with apnea and hypotension.

Convulsions are more likely to occur after brachial plexus block and epidural block. This can most likely be the result of accidental intravascular administration or rapid absorption at the injection site.

Peripheral nerve blocks may require large volumes of local anesthetic to areas with many vessels, often near major vessels, increasing the risk of intravascular injection and/or rapid systemic absorption, which can lead to high plasma concentrations.

Some local anesthetic procedures, such as head and neck injections, may be associated with an increased incidence of serious adverse reactions, regardless of the anesthetic used. Care must be taken to prevent injection in the area of inflammation.

Elderly and debilitated patients, patients with intracardiac conduction block of degree II and III, and patients with severe renal insufficiency require special attention, but local anesthesia is often indicated for these patients.

There have been isolated reports of cardiac arrest when using ropivacaine for epidural anesthesia or peripheral nerve block, especially after accidental intravascular injection in elderly patients and patients with comorbid heart disease.

In some cases, resuscitation measures may be difficult. If cardiac arrest, effective resuscitation may take a long time.

Ropivacaine is metabolized in the liver and therefore should be used with caution in patients with liver disease; repeated doses may need to be reduced due to delayed excretion.

There is usually no need to adjust the dosage in patients with renal and hepatic impairment during single or short-term therapy. However, acidosis and decreased plasma protein concentrations, often seen in patients with chronic renal failure, may increase the risk of systemic intoxication.

Spinal anesthesia may result in decreased blood pressure (BP) and bradycardia. Administration of vasoconstrictors or increased circulating blood volume may reduce the risk of these side effects. Arterial hypotension should be promptly corrected by administration of 5-10 mg of ephedrine; if necessary, the administration may be repeated.

Possible cross-sensitivities with other amide-type anesthetics should be taken into account – the type of local anesthetic should be taken into account.

Patients on a sodium-restricted diet should take into account the sodium content of the drug.

The use of the drug in concentrations above 5 mg/ml, as well as intrathecal administration of Ropivacaine Kabi in children has not been studied.

Ropivacaine Kabi Injection Solution may have porphyrinogenic properties and should only be used in patients diagnosed with acute porphyria if there is no safer alternative. If patients are hypersensitive, necessary precautions should be taken.

Indicate, if necessary, special precautions for the disposal of unused medications

Unused solution must be disposed of in accordance with the current drug disposal requirements of the hospital in question.

Potentially hazardous activities requiring increased attention and rapid psychomotor reactions should be refrained from, as motor function, motor coordination and reaction speed are temporarily impaired.

Contraindications

With caution

Elderly patients, patients in a weakened state or patients with severe comorbidities, including Grade II and III intracardiac conduction blockages (sinoatrial, atrioventricular, intraventricular), advanced liver disease, severe hepatic failure, severe chronic renal failure, acute porphyria, during therapy of hypovolemia, weakened patients, elderly, childhood, pregnancy and during lactation.

The use of regional anesthesia is preferable for these groups of patients. When performing “large” blocks, in order to reduce the risk of severe adverse events, it is recommended to stabilize the patient’s condition beforehand and to adjust the anesthetic dose.

Caution should be exercised when injecting local anesthetics into the head and neck region because of the possible increased frequency of serious adverse events.

Patients on a sodium-restricted diet should consider the sodium content of the drug.

Side effects

Adverse reactions to Ropivacaine Kabi are similar to those to other amide-type local anesthetics. Adverse reactions must be distinguished from physiological effects of the block itself, such as hypotension and bradycardia during subdural anesthesia, or effects associated with the technique of drug administration (e.g., spinal hematoma, local nerve damage, headache after subdural puncture, meningitis and epidural abscess).

Side effects common to local anesthetics

Central and peripheral nervous system disorders

Neuropathy and spinal cord dysfunction (anterior spinal artery syndrome, arachnoiditis, cauda equina syndrome) are possible, usually related to the technique of regional anesthesia rather than the action of the drug.

The accidental intrathecal administration of a dose in excess of the recommended dose may result in complete spinal block. Serious complications are possible with systemic overdose and unintentional intravascular administration of the drug (see section “Overdose”).

Acute systemic toxicity

Ropivacaine Kabi may cause acute systemic toxic reactions if high doses are used or if its blood concentration rises rapidly if the drug is inadvertently administered intravascularly or in overdose (see “Pharmacological properties” and “Overdose”).

The most frequently reported side effects of the drug

A variety of side effects have been reported, with the vast majority not related to the anesthetic agent used but to the regional anesthetic technique.

The most frequently reported adverse effects (>1%) were the following, which were considered to be clinically significant regardless of whether a causal relationship with anesthetic use was established: decreased BP*, nausea, bradycardia, vomiting, paresthesia, increased body temperature, headache, urinary retention, dizziness, chills, increased BP, tachycardia, hypoesthesia, anxiety.

The incidence of adverse effects is as follows: Very common – >1/10; common – >1/100 to <1/10; infrequent – >1/1000 to <1/100; rare – >1/10 000 to <1/1 000; very rare – <1/10 000; unknown – cannot be determined based on available data.

Nervous system disorders: frequent – headache, paresthesia, dizziness; infrequent – anxiety, symptoms of CNS toxicity (seizures, grand convulsive seizures, peroral paresthesia, tongue numbness, hyperacusis, tinnitus, visual disturbances, dysarthria, muscle twitches, tremor)*, hypoesthesia.

Chronic disorders: very common – decreased BP (hypotension); common – bradycardia, tachycardia, increased BP; infrequent – syncope; rare – cardiac arrest, arrhythmia.

Disorders of the respiratory system, thorax and mediastinum: infrequent – dyspnea, difficulty in breathing.

Gastrointestinal disorders: very common – nausea; common – vomiting.

River and urinary tract disorders: frequently – urinary retention.

General disorders and disorders with administration: frequently – back pain, hyperthermia, chills; infrequently – hypothermia; rarely – allergic reactions (anaphylactic reactions. angioedema and urticaria).

* These symptoms are usually associated with accidental intravascular administration, overdose, or rapid absorption.

a – Hypotension in children is common (>1/100).

b – Vomiting in children is very common (>1/10).